ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Risedronate attenuates renal fibrosis by targeting prenylation-dependent RhoA/ROCK1 and ERK/NF-κB signaling.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Establishment and characterization of mouse lymph node fibrosis models.Animal models and experimental medicine · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Chronic kidney disease (CKD) is a global health concern with rising morbidity and mortality. The repurposing of drugs offers a valuable opportunity to accelerate therapeutic development in CKD. Risedronate (RIS), a nitrogen-containing bisphosphonate approved to prevent and treat bone-related conditions, has therapeutic potential in CKD. Hence, we aimed to investigate the potential of RIS in unilateral ureteral obstruction (UUO)-induced renal fibrosis in Sprague-Dawley (SD) rats and recombinant human-transforming growth factor-β1 (rh-TGF-β1)-induced fibrosis in normal rat kidney epithelial cells (NRK-52E). Following randomization, animals were subjected to sham, UUO, and UUO + RIS (5 µg/kg, s.c., twice weekly) for 21 days. Post-treatment, plasma, urine, and kidney tissue samples were collected for subsequent biochemical, histological, and immunohistochemical analysis. Additionally, NRK-52E cells were divided into a normal control (NC), rh-TGF-β1, and rh-TGF-β1 + RIS (10 µM) groups for 48 h, and cell samples were harvested for cell viability, cell morphology, and immunocytochemistry assay. RIS treatment notably restored the kidney mass ratio and kidney function parameters, and histopathological studies showed that RIS significantly preserved the kidney structure in UUO rats. While RIS treatment notably suppresses the levels of FPPS, p-NF-κB, TNF-α, IL-6, TGF-β, and CTGF, as well as collagen and fibronectin, as proven by immunohistochemistry, ELISA, and qRT-PCR in UUO rats. Moreover, immunocytochemistry suggested that RIS inhibits protein prenylation-dependent expression of p-ERK 1/2, RhoA, and ROCK1 in NRK-52E cells. Indeed, the study findings indicated that RIS treatment modulated renal fibrosis by targeting prenylation-dependent RhoA/ROCK1 and ERK/NF-κB signaling axis, holding the clinical promise in CKD management.
Indexed as
Identifiers
41343045What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.